CTSO vs. STIM, SMTI, ZIMV, RCEL, SNWV, NVRO, NYXH, ELMD, PDEX, and DRTS
Should you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include Neuronetics (STIM), Sanara MedTech (SMTI), ZimVie (ZIMV), AVITA Medical (RCEL), SANUWAVE Health (SNWV), Nevro (NVRO), Nyxoah (NYXH), Electromed (ELMD), Pro-Dex (PDEX), and Alpha Tau Medical (DRTS). These companies are all part of the "medical equipment" industry.
Cytosorbents vs.
Neuronetics (NASDAQ:STIM) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership.
53.6% of Neuronetics shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 9.8% of Neuronetics shares are held by company insiders. Comparatively, 6.6% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Cytosorbents received 312 more outperform votes than Neuronetics when rated by MarketBeat users. Likewise, 73.26% of users gave Cytosorbents an outperform vote while only 68.62% of users gave Neuronetics an outperform vote.
Cytosorbents has lower revenue, but higher earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
Neuronetics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.
Cytosorbents has a net margin of -49.47% compared to Neuronetics' net margin of -50.09%. Cytosorbents' return on equity of -118.54% beat Neuronetics' return on equity.
In the previous week, Neuronetics and Neuronetics both had 3 articles in the media. Cytosorbents' average media sentiment score of 0.47 beat Neuronetics' score of 0.47 indicating that Cytosorbents is being referred to more favorably in the news media.
Neuronetics presently has a consensus price target of $5.50, suggesting a potential upside of 24.58%. Cytosorbents has a consensus price target of $4.67, suggesting a potential upside of 340.25%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts clearly believe Cytosorbents is more favorable than Neuronetics.
Summary
Cytosorbents beats Neuronetics on 11 of the 17 factors compared between the two stocks.
Get Cytosorbents News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytosorbents Competitors List
Related Companies and Tools
This page (NASDAQ:CTSO) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy CTSO Stock Free CTSO Stock Alerts